GlassScriptPhysician profile
Toni R Peters
NPI 1770953291
$5,902.87
in general payments reported to CMS, 2019-2025
24 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $775 · 2022: $998 · 2023: $1,376 · 2024: $1,405 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,114 · Education: $15.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,114.48 |
| Education | $15.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $927.19 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $809.67 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $588.83 | 2021-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $557.43 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $526.55 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $444.52 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $434.62 | 2022-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $293.01 | 2023-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $283.17 | 2021-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $186.46 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $182.52 | 2022-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $176.59 | 2022-2024 | Quviviq |
| Noven Therapeutics, LLC | $98.09 | 2023-2025 | Xelstrym |
| Corium, LLC | $62.33 | 2023-2024 | Azstarys |
| Biogen, INC. | $56.89 | 2025 | Zurzuvae |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $52.46 | 2022-2025 | |
| Ironshore Pharmaceuticals INC. | $47.21 | 2022-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $35.95 | 2022-2024 | Qelbree |
| Tris Pharma INC | $34.61 | 2023-2025 | Dyanavel Xr |
| Almatica Pharma LLC | $33.97 | 2022-2025 | Loreev Xr |
| Avanir Pharmaceuticals, INC. | $19.05 | 2021 | |
| Indivior INC. | $18.00 | 2021 | |
| Bausch Health US, LLC | $17.30 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toni Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.